Advancing Therapy for Pulmonary Arterial Hypertension: Can Animal Models Help?

American Journal of Respiratory and Critical Care Medicine

Volumn 169, Issue 1, 2004, Pages 5-6

  Robbins, Ivan M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BERAPROST; BONE MORPHOGENETIC PROTEIN 2; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; MONOCROTALINE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL;

ANIMAL MODEL; ANTIHYPERTENSIVE THERAPY; ARTERY DILATATION; ARTERY ENDOTHELIUM; DRUG MECHANISM; EDITORIAL; ENDOTHELIUM INJURY; GENE MUTATION; GERM LINE; HEREDITARY HYPERTENSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; EPOPROSTENOL; HYPERTENSION, PULMONARY; MALE; PIPERAZINES; RANDOM ALLOCATION; RATS; RATS, WISTAR; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 1242320991     PISSN: 00030805     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (16)

1. Pietra GG, Edwards WD, Kay JM, Rich S, Kernis J, Schloo B, Ayers SM, Bergofsky EH, Brundage BH, Detre KM, et al. Histopathology of primary pulmonary hypertension: a qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute. Primary Pulmonary Hypertension Registry. Circulation 1989;80:1198-1206.
2. Nishimura T, Vaszar LT, Faul JL, Zhao G, Berry GJ, Shi L, Qiut D, Benson G, Pearl RG, Kao PN. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003;108:1640-1645.
3. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477-1482.
4. Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003;167:580-586.
5. Lugnier C, Keravis T, Eckly-Michel A. Cross talk between NO and cyclic nucleotide phosphodiesterases in the modulation of signal transduction in blood vessel. Physiol Pharmacol 1999;50:639-652.
6. Itoh T, Nagaya N, Fujii T, Iwase T, Nakanishi N, Hamada K, Kangawa K, Kimura H. A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;169:34-38.
7. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, Weissmann N, Ghofrani S, Enke B, Seeger W, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003;42:158-164.
8. Humbert M, Barst RJ, Robbins IM, Channick R, Manes A, Rubin LJ, Galie N, Booonstra A, Badesch D, Frost A, et al. Safety & efficacy of bosentan combined with epoprostenol in patients with severe pulmonary arterial hypertension [abstract]. Am J Respir Crit Care Med 2003;167:A441.
9. Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F, Simonneau G, Dartevelle P, Hamon M, Adnot S. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001;108:1141-1150.
10. Morrell NW, Yang X, Upton PD, Jourdan KB, Morgan N, Sheares KK, Trembath RC. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation 2001;104:790-795.
11. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA III, Loyd JE, Nichols WC, Trembath RC. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension: the International PPH Consortium. Nat Genet 2000;26:81-84.
12. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, Kalachikov S, Cayanis E, Fischer SG, Barst RJ, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;67:737-744.
13. Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, Elliott GC, Ward K, Yacoub M, Mikhail G, Rogers P, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000;37:741-745.
14. Eddahibi S, Hanoun N, Lanfumey L, Lesch KP, Raffestin B, Hamon M, Adnot S. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest 2000;105:1555-1562.
15. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, Funk GC, Hamilton G, Novotny C, Burian B, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003;111:1339-1346.
16. Geraci MW, Gao B, Shepherd DC, Moore MD, Westcott JY, Fagan KA, Alger LA, Tuder RM, Voelkel NF. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest 1999;103:1509-1515.